Influenza differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohammad Braizat, M.S. [2]

Influenza is an acute respiratory illness caused by influenza viruses (types A, B, C, and D) that circulates seasonally worldwide. In most patients, influenza is self-limited, but it can cause severe illness and death, particularly in high-risk populations. The annual global burden of seasonal influenza includes an estimated 3-5 million cases of severe illness and 290,000-650,000 respiratory deaths. The clinical presentation overlaps with numerous other respiratory pathogens, making laboratory confirmation important for diagnosis and management.

Fever is the most discriminating clinical feature of influenza compared to other common respiratory viruses. In a 2026 cohort study of hospitalized adults, fever on admission was significantly more common in influenza patients compared to those with respiratory syncytial virus (RSV), and influenza patients more frequently reported myalgia, headache, sore throat, and gastrointestinal symptoms.^[1] Conversely, RSV patients more often presented with sputum production, dyspnea, wheezing, and radiographic evidence of infection.^[1]

Rhinovirus infections present with more upper respiratory symptoms than influenza. A 2025 study found that nasal discharge, sore throat, nasal congestion, sneezing, hoarseness, headache, and myalgia were significantly more common in rhinovirus infection, while fever was significantly higher in influenza (both types A and B).^[2] Cough was common in both but more frequent in influenza A than influenza B.^[2]

Human metapneumovirus (HMPV) and RSV share clinical overlap with influenza but differ in key features. In a French primary care study of 5,859 patients with influenza-like illness, cough was associated with influenza (OR 2.14), RSV (OR 2.52), and HMPV (OR 2.15), while rhinorrhea was primarily associated with human rhinovirus detection (OR 1.75).^[3] Headache was associated with influenza detection (OR 1.75), whereas absence of headache was associated with RSV and HMPV. Dyspnea was associated with RSV (OR 2.33) and absence of dyspnea with influenza.^[3]

No individual clinical feature is pathognomonic for any respiratory virus. A 2018 systematic review and prospective cohort study of 6,073 children with influenza-like illness confirmed that while certain features show statistical associations with specific viruses—fever and headache with influenza, cough and wheezing with RSV, rhinitis with rhinovirus—substantial overlap exists across all pathogens. The authors concluded that laboratory confirmation remains essential, as clinical features alone cannot reliably rule in or rule out any particular viral infection.^[4]

The most validated ILI case definition for influenza detection is fever plus cough. A 2015 study of 1,581 emergency department patients found that the best predictive model for laboratory-confirmed influenza included cough (DOR 5.87), fever (DOR 4.49), rhinorrhea (DOR 1.98), and myalgias (DOR 1.44).^[5] Case definitions combining these symptoms achieved sensitivity of 89-92% and specificity of 38-44%.^[5] For children under 5 years, adding rhinorrhea to fever and cough improved the balance between sensitivity (85%) and specificity (47%).^[5]

COVID-19 and influenza have overlapping but distinguishable clinical presentations. A 2021 global meta-analysis of 75,164 COVID-19 cases, 113,818 influenza A cases, and 9,266 influenza B cases found that runny nose, dyspnea, sore throat, and rhinorrhea were less frequent in COVID-19 (14%, 15%, 11.5%, and 9.5%, respectively) compared to influenza A (70%, 45.5%, 49%, and 44.5%) and influenza B (74%, 33%, 38%, and 49%).^[6]

Radiographic findings differ significantly. Most COVID-19 patients (84%) had abnormal chest imaging compared to influenza A (57%) and influenza B (33%).^[6] COVID-19 demonstrated longer incubation period (6.4 days vs. 3.4 days for influenza A) and longer hospitalization duration (14 days vs. 6.5 days for influenza A and 6.7 days for influenza B).^[6]

Specific CT features favor COVID-19 over influenza pneumonia. A 2022 study found that crazy-paving pattern, pure ground-glass opacities (GGO) in peripheral areas, pure GGO, lesion sizes 1-3 cm, emphysema, and pleural traction were significantly associated with COVID-19.^[7] A combined model using CT features and clinical variables (temperature and white blood cell count) achieved an AUC of 0.991 in differentiating COVID-19 from influenza pneumonia.^[7]

Clinical features alone cannot reliably differentiate viral from bacterial pneumonia. However, certain patterns may suggest bacterial etiology:

• Atypical bacterial pneumonias (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila) present with gradual onset, prominent cough, and less severe systemic symptoms compared to influenza's abrupt onset with high fever and myalgias. Legionella infection is associated with hyponatremia, abnormal liver function tests, confusion, and diarrhea—features less common in uncomplicated influenza.

• Typical bacterial pneumonia (Streptococcus pneumoniae, Staphylococcus aureus) may follow influenza as a secondary infection, presenting with worsening symptoms after initial improvement, productive cough with purulent sputum, focal consolidation on imaging, and elevated white blood cell count with neutrophilia.

Molecular assays are preferred over rapid antigen tests, especially in hospitalized patients. The Infectious Diseases Society of America (IDSA) and American Society for Microbiology (ASM) 2024 update on diagnostic microbiology provides comprehensive guidance on laboratory testing for influenza.^[8] For adult patients, molecular assays (e.g., RT-PCR) are the preferred diagnostic modality for hospitalized patients and those with risk factors for severe disease.

The American Academy of Pediatrics (AAP) 2023-2024 and 2025-2026 guidelines recommend that hospitalized patients with signs and symptoms of influenza should be tested with a molecular assay with high sensitivity and specificity when influenza is circulating in the community.^[9][10] Rapid molecular assays are highly sensitive and preferred over rapid influenza diagnostic tests (RIDTs) in ambulatory children.^[9][10]

RIDTs have suboptimal sensitivity (50-70%) in ambulatory settings.^[10] The 2025-2026 AAP guidelines state: "The typical sensitivity of a rapid test performed in a physician's office is 50% to 70%."^[10] During periods of high community influenza activity, clinicians should consider confirming negative RIDTs with a molecular test due to suboptimal sensitivity and potential for false-negative results.^[11][9]

Positive and negative predictive values are influenced by the level of influenza activity in the population being tested. During periods of low community influenza prevalence, positive results are more likely to be false positives; during high prevalence, negative results are more likely to be false negatives.^[10][11] Clinicians interpreting test results should consider the local epidemiology.

Multiplex assays are valuable when multiple respiratory viruses cocirculate. Multiplex assays that simultaneously detect influenza viruses, SARS-CoV-2, and RSV are particularly useful when these viruses cocirculate, as clinical differentiation is difficult and different treatment strategies are recommended.^[11][9][10]

Given the ongoing H5N1 outbreak in 2025-2026, the AAP guidelines recommend expedited subtyping of influenza A specimens from hospitalized patients to evaluate for H5 infection.^[10] Clinicians should be aware of local and national surveillance systems for novel influenza A viruses and coordinate with public health authorities when H5 infection is suspected.

The FDA has granted emergency use authorization for at-home multiplex tests detecting influenza A/B and SARS-CoV-2 in children as young as 2 years.^[10] These tests may facilitate early detection but should be interpreted with caution given the sensitivity limitations of rapid antigen tests.

Several non-infectious conditions may mimic influenza:

• Drug-induced flu-like illness: Interferons, monoclonal antibodies, bisphosphonates, and chemotherapeutic agents can cause fever, myalgias, and fatigue
• Vaccination reactions: Typically transient and mild, occurring within 24-48 hours of immunization
• Pulmonary embolism: May present with dyspnea, chest pain, and tachycardia; consider in patients with risk factors
• Acute exacerbations of chronic lung disease (asthma, COPD): Dyspnea and cough prominent; history of underlying lung disease
• Myocarditis/pericarditis: Chest pain, dyspnea; may follow viral prodrome; elevated cardiac biomarkers
• Hematologic malignancies: Fever, fatigue, night sweats; cytopenias on CBC

• Fever is the most discriminating feature for influenza versus other common respiratory viruses; prominent upper respiratory symptoms (rhinorrhea, nasal congestion, sneezing) favor rhinovirus or common cold.^[2][3]
• Fever plus cough is the most validated ILI case definition, achieving 89-92% sensitivity for influenza detection.^[5]
• RIDT sensitivity is only 50-70%: Negative rapid antigen tests do not rule out influenza during periods of high community activity; consider molecular confirmation.^[10][9]
• RSV patients are typically older, more comorbid, and present with more dyspnea and wheezing than influenza patients, despite similar mortality risk.^[1]
• COVID-19 typically presents with less rhinorrhea and sore throat than influenza, longer incubation period, and more frequent abnormal chest imaging.^[6]
• Multiplex testing is preferred when influenza, COVID-19, and RSV cocirculate because clinical differentiation is unreliable and treatment strategies differ.^[11][9][10]
• Hyponatremia, abnormal liver function tests, confusion, and diarrhea suggest Legionella rather than influenza.
• PPV/NPV vary with prevalence: During low influenza activity, positive test results may be false positives; during high activity, negative results may be false negatives.^[10]

• Relying on clinical diagnosis alone when laboratory testing is available; no symptom combination reliably excludes influenza.^[4]
• Accepting negative RIDTs without confirmation during high influenza activity periods; RIDTs have suboptimal sensitivity (50-70%).^[10][11][9]
• Failing to consider COVID-19 in the differential diagnosis of ILI; overlapping presentations require multiplex testing for accurate diagnosis.^[7][6]
• Assuming absence of fever rules out influenza; while fever is common, some influenza patients present without documented fever, particularly elderly or immunocompromised individuals.
• Not considering secondary bacterial pneumonia in influenza patients who initially improve then worsen; this represents a distinct clinical entity requiring antibacterial therapy.
• Testing during low influenza prevalence without considering the increased risk of false-positive results.^[9][10]
• Overlooking non-infectious causes of flu-like illness, particularly drug-induced reactions in patients on interferons, monoclonal antibodies, or chemotherapy.
• Failing to consider H5 avian influenza in hospitalized patients with influenza A during the 2025-2026 outbreak; expedited subtyping is recommended.^[10]